ClinicalTrials.gg
CompletedNCT04933565Updated Jan 17, 2023

First in Human Study of ORG-129 in Healthy Volunteers

A Phase 1 interventional study of ORG-129 and Placebo in Healthy Volunteers, sponsored by Origo Biopharma. Completed at 1 site in Spain. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-17.

Sponsored by Origo Biopharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The current study is performed to characterize the safety, tolerability and pharmacokinetics of ORG-129 after oral intake in healthy male and female volunteers after single ascending and multiple ascending doses.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

This is the only study on the registry with Origo Biopharma as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in the Single Dose Study, subjects should meet all the following criteria at the screening visit:

  1. Healthy male subjects, 18-45 years (inclusive) of age at the time of enrolment.
  2. Body weight within normal range (Quetelet's index between 19 and 27) expressed as weight (kg) / height (m2).
  3. Normal clinical records and physical examination.
  4. Laboratory tests (hematology and biochemistry) within the range of normal values, according to the Biochemistry laboratory reference values of the 'Hospital de la Santa Creu i Sant Pau'. Variations may be admitted according to the clinical criteria of the CIM-Sant Pau.
  5. Clinically acceptable temperature, blood pressure and pulse rate in supine and standing position (SBP between 100-140 mm Hg/ DBP between 50-90 mm Hg / HR between 50- 100 bpm). Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.
  6. Males should agree to abstain from sexual intercourse with a female partner or agree to use a condom with spermicide, in addition to having their female partner using some measures as oral contraceptive drugs, intrauterine hormonal contraception, or cervical caps until 28 days post-administration.
  7. To be able to understand the nature of the study and comply with all their requirements.
  8. Free acceptance to participate in the study should be stated in an document signed by the volunteer which must be approved by the CREC.

For the Multiple Dose Study, subjects should meet all the following inclusion criteria at screening visit:

  1. Healthy male/female subjects, 18-45 years (inclusive) of age at the time of enrolment.
  2. Body weight within normal range (Quetelet's index between 19 and 27) expressed as weight (kg) / height (m2).
  3. Normal clinical records and physical examination at screening and baseline.
  4. Laboratory tests (hematology, biochemistry and urianalysis) within the range of normal values, according to the laboratory reference values of the 'Hospital de la Santa Creu i Sant Pau'. Variations may be admitted according to the clinical criteria of the CIM-Sant Pau.
  5. Clinically acceptable temperature, blood pressure and pulse rate in supine and standing position (SBP between 100-140 mm Hg/ DBP between 50-90 mm Hg / HR between 50- 100 bpm). Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.
  6. Males should agree to abstain from sexual intercourse with a female partner or agree to use a condom with spermicide, in addition to having their female partner using some contraceptive measures as oral contraceptive drugs, intrauterine hormonal contraception, or cervical caps until 28 days post-administration.
  7. Females must be of non- (i.e., surgically sterile) or have to use contraceptive measures (non-hormonal) such as condom, diaphragm or cervical/vault cap with spermicide until 28 days post-administration.
  8. To be able to understand the nature of the study and comply with all their requirements.
  9. Free acceptance to participate in the study by obtains signed informed consent form approved by the CREC.

Exclusion criteria

Exclusion Criteria:

For the single dose study and multiple dose study meeting any of the following criteria at screening visit will be excluded from entry into the study:

  1. History of alcohol dependence or drug abuse in the last 5 years or daily consumption of alcohol > 40 gr/day for men and >24 for women (in MAD).
  2. Heavy consumer of stimulating beverages (>5 coffees, teas, chocolate or cola drinks per day) and grape juice.
  3. Background of idiosyncrasy, food intolerance, or adverse reactions to any drug or galenical form.
  4. Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
  5. Intake of any medication within 2 weeks prior taking the study treatment (except for use of paracetamol in short-term symptomatic treatments), including over-the-counter products (including natural food supplements, vitamins and medicinal plants products), or any enzymatic inductor or inhibitor within 3 months before the drug administration.
  6. Positive serology for , C or .
  7. Background or evidence of cardiovascular, respiratory, renal, hepatic, endocrine, gastrointestinal, hematological, neurological disease or other chronic diseases.
  8. History of psychiatric diseases or epileptic seizures.
  9. 12 lead obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and ≥ 440 msec, bradycardia (\<50 bpm) or clinically significant minor ST wave changes or any other abnormal changes on the screening ECG that would interfere with measurement of the QT interval.
  10. Having undergone major surgery during the previous 6 months.
  11. Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc.) from 6 months prior to drug administration.
  12. Participation in other clinical trials during the previous 90 days (last drug to first drug administration period) in which an drug or a commercially available drug was tested.
  13. Donation of blood during the 4 weeks preceding the drug administration.
  14. Severe or moderate acute illness 4 weeks before drug administration.
  15. Clinically significant infections within 3 months or any infection within 28 days of screening.
  16. History or recurrent disseminated herpes simplex or herpes zoster.
  17. Personal or family history of hereditary immunodeficiency
  18. Clinically significant abnormal laboratory values (as determined by the PI) at the screening evaluation.
  19. Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract
  20. Positive results of the drugs at screening period or the day before starting treatment period. A minimum list of 6 drugs will be screened for inclusion: Amphetamines, Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be repeated at the discretion of the PI).
  21. Females with positive results from the pregnancy test or breast-feeding (MAD).
  22. Females with hormonal therapy.
  23. Positive Covid-19 diagnosis prior to hospital admission
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    ORG-129

    Single ascending dose (up to 4 cohorts), Multiple ascending dose (up to 4 cohorts), Food interaction cohort, Multiple dose PK/PD cohort

    Drug: ORG-129

  • Placebo comparator
    Placebo

    Single ascending dose (up to 4 cohorts), Multiple ascending dose (up to 4 cohorts), Food interaction cohort, Multiple dose PK/PD cohort

    Drug: Placebo

Interventions

  • ORG-129 oral capsules

  • DrugPlacebo

    Placebo oral capsules

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of SAD of ORG-129

    by assessing the number, severity and type of treatment emergent adverse events

    Time frame: day 1 through day 8

  2. To assess the safety and tolerability of MAD of ORG-129

    by assessing the number, severity and type of treatment emergent adverse events

    Time frame: day 1 through day 12

Secondary outcomes

  1. Pharmacokinetics of ORG-129 when given as SAD: AUC

    Area under the plasma concentration-time curve (AUC)

    Time frame: Day 1 and Day 2

  2. Pharmacokinetics of ORG-129 when given as SAD: Cmax

    Maximum observed concentration (Cmax)

    Time frame: Day 1 and Day 2

  3. Pharmacokinetics of ORG-129 when given as SAD: Tmax

    Time to reach maximum observed concentration (Tmax)

    Time frame: Day 1 and Day 2

  4. Pharmacokinetics of ORG-129 when given as SAD: CL/F

    Oral Clearance (CL/F)

    Time frame: Day 1 and Day 2

  5. Pharmacokinetics of ORG-129 when given as SAD: Vz/F

    Terminal Phase Volume of Distribution(Vz/F)

    Time frame: Day 1 and Day 2

  6. Pharmacokinetics of ORG-129 when given as SAD: Kel

    Elimination Rate (Kel)

    Time frame: Day 1 and Day 2

  7. Pharmacokinetics of ORG-129 when given as SAD: t 1/2

    Elimination Halflife (t 1/2)

    Time frame: Day 1 and Day 2

  8. Pharmacokinetics of ORG-129 when given as MAD: AUC

    Area under the plasma concentration-time curve (AUC)

    Time frame: Day 1 and Day 5

  9. Pharmacokinetics of ORG-129 when given as MD: AUC

    Area under the plasma concentration-time curve (AUC)

    Time frame: Day 1 and Day 10

  10. Pharmacokinetics of ORG-129 when given as MAD: Cmax

    Maximum observed concentration (Cmax)

    Time frame: Day 1 and Day 5

  11. Pharmacokinetics of ORG-129 when given as MD: Cmax

    Maximum observed concentration (Cmax)

    Time frame: Day 1 and Day 10

  12. Pharmacokinetics of ORG-129 when given as MAD: Tmax

    Time to reach maximum observed concentration (Tmax)

    Time frame: Day 1 and Day 5

  13. Pharmacokinetics of ORG-129 when given as MD: Tmax

    Time to reach maximum observed concentration (Tmax)

    Time frame: Day 1 and Day 10

  14. Pharmacokinetics of ORG-129 when given as MAD: CL/F

    Oral Clearance (CL/F)

    Time frame: Day 1 and Day 5

  15. Pharmacokinetics of ORG-129 when given as MD: CL/F

    Oral Clearance (CL/F)

    Time frame: Day 1 and Day 10

  16. Pharmacokinetics of ORG-129 when given as MAD: Vz/F

    Terminal Phase Volume of Distribution(Vz/F)

    Time frame: Day 1 and Day 5

  17. Pharmacokinetics of ORG-129 when given as MD: Vz/F

    Terminal Phase Volume of Distribution(Vz/F)

    Time frame: Day 1 and Day 10

  18. Pharmacokinetics of ORG-129 when given as MAD: Kel

    Elimination Rate (Kel)

    Time frame: Day 1 and Day 5

  19. Pharmacokinetics of ORG-129 when given as MD: Kel

    Elimination Rate (Kel)

    Time frame: Day 1 and Day 10

  20. Pharmacokinetics of ORG-129 when given as MAD: t 1/2

    Elimination Halflife (t 1/2)

    Time frame: Day 1 and Day 5

  21. Pharmacokinetics of ORG-129 when given as MD: t 1/2

    Elimination Halflife (t 1/2)

    Time frame: Day 1 and Day 10

  22. Pharmacokinetics of ORG-129 when given as MAD: Css

    concentration at steady state (Css)

    Time frame: Day 5

  23. Pharmacokinetics of ORG-129 when given as MD: Css

    concentration at steady state (Css)

    Time frame: Day 10

  24. PK of ORG-129 when given as MAD: C trough [ Time Frame: Day 2, 5 ]

    C trough

    Time frame: Day 2 and Day 5

  25. PK of ORG-129 when given as MD: C trough [ Time Frame: Day 2, 10 ]

    C trough

    Time frame: Day 2 and Day 10

  26. PD of ORG-129 when given as MD [ Time Frame: Day 2, 10 ]

    Biomarker analysis

    Time frame: Day 1-10

07

Study locations

1 site
  • Institut de Recerca de l'Hospital de la Santa Creu i de Sant Pau
    Barcelona, Catalonia 08025, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Dec 2022, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2021
First posted
Jun 21, 2021
StartActual
Jun 1, 2021
Primary completionActual
Dec 12, 2022
CompletionActual
Jan 9, 2023
Last update
Jan 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04933565
Lead sponsor
Origo Biopharma
Responsible party
Sponsor
First posted
Jun 21, 2021
Start date
Jun 1, 2021
Primary completion
Dec 12, 2022
Completion
Jan 9, 2023
Last update
Jan 17, 2023

Study contacts

Juan Martinez-Colomer, MD
principal investigator · Institut de Recerca de l'Hospital de la Santa Creu i de Sant Pau

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ontunisertib

Start the discussion